It’s only fair to share… Azeliragon C32H38ClN3O2, 532.1 g/mol CAS 603148-36-3 TTP488 UNII-LPU25F15UQ LPU25F15UQ TTP-488; PF-04494700 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine MOA：RAGE inhibitor Indication：Alzheimer’s disease (AD) Status：Phase III (Active), Dementia, Alzheimer’s type Company：vTv Therapeutics (Originator) Azeliragon Azeliragon is in phase III clinical for the treatment of Alzheimer’s type dementia. Azeliragon was originally by TransTech Pharma (now vTv Therapeutics), then licensed to Pfizer in …